Get the Stockscreener App
1.35
6.25%
-0.09
Jaguar Health Inc stock is traded at $1.35, with a volume of 185.50K.
It is down -6.25% in the last 24 hours and down -22.86% over the past month.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
See More
Previous Close:
$1.44
Open:
$1.45
24h Volume:
185.50K
Relative Volume:
0.90
Market Cap:
$5.04M
Revenue:
$10.48M
Net Income/Loss:
$-37.74M
P/E Ratio:
-0.0834
EPS:
-16.1846
Net Cash Flow:
$-29.03M
1W Performance:
+25.00%
1M Performance:
-22.86%
6M Performance:
-64.75%
1Y Performance:
-94.46%
1-Day Range:
$1.32
$1.50
1-Week Range:
$1.05
$1.50
52-Week Range:
$1.00
$33.25
Jaguar Health Inc Stock (JAGX) Company Profile
Name
Jaguar Health Inc
Sector
Industry
Phone
415-371-8300
Address
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Compare JAGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
1.35 | 5.38M | 10.48M | -37.74M | -29.03M | -16.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
Jaguar Health Inc Stock (JAGX) Latest News
Jaguar Health Executes Strategic Stock Exchange Agreements - TipRanks
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs - The Florida Times-Union
Jaguar Health Inc (JAGX) is looking forward to a strong quarter - setenews.com
Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders - azcentral.com and The Arizona Republic
Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones - The Florida Times-Union
FDA extends conditional approval for Jaguar Health’s canine drug By Investing.com - Investing.com Australia
FDA extends conditional approval for Jaguar Health’s canine drug - Investing.com
Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts - Daytona Beach News-Journal
Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates - Bluffton Today
Jaguar Health announces promising trial results for crofelemer - MSN
Jaguar Health Announces Promising Trial Results for Crofelemer - TipRanks
Jaguar Health (NASDAQ: JAGX) clears all special meeting items, notes MVID trial progress - Stock Titan
Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue - Livingston Daily
REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners’ Spring 2025 Spotlight Series - Daily Commercial
Sakthi Sugars Limited (SAKHTISUG) vs yyyFibonacci Extensions & Free Gain Edge With Data - earlytimes.in
JAGX S-3/A及美國證券交易委員會申報文件 - Yahoo 財經
How dovish Fed policy supports Jaguar Health Inc. (1JA0) stockJuly 2025 Sector Moves & Real-Time Market Sentiment Alerts - Newser
Is Jaguar Health Inc. stock near bottom after declineWeekly Gains Summary & Weekly Sector Rotation Insights - Newser
Jaguar Health (JAGX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Jaguar Health, Inc. (JAGX) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
JAGX S-3及美國證券交易委員會申報文件 - Yahoo 財經
Jaguar Health to Hold Investor Webcast Thursday, August 14 at 8:30 AM Eastern Regarding Q2 2025 Financials & Corporate Updates - Montgomery Advertiser
Is Jaguar Health Inc (JAGX) positioned for future growth? - Setenews
How Jaguar Health Inc. (1JA0) stock responds to job market shiftsDip Buying & Fast Gain Stock Tips - Newser
Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study - Daily American
Jaguar Health Inc Stock (JAGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):